Biomarker ID | 50 |
PMID | 15609297 |
Year | 2005 |
Biomarker | GalNAc-T3+PSMA+Hepsin+DD3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(GALNT3):-O-glycan biosynthesis,O-linked glycosylation of mucins, Post-translational protein modif,Protein met,Interleukin-2 signaling pathwayabolismication |
Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 18 patients with prostate cancer and 32 patients woth Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
Senstivity | BPH Prediction: 100% |
Specificity | PCa Prediction: 100% |
AUC | NA |
Accuracy | 10000% |
Level Of Significance | NA |
Method Used | RT-PCR |
Clinical | No |
Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | GALNT3, PSMA, Hepsin, PCA3 |